Evidence map›Paper›PMID 30609850›Full record

ReviewCancers2019

Gut Microbiota and Cancer: From Pathogenesis to Therapy.

Silvia Vivarelli, Rossella Salemi, Saverio Candido, Luca Falzone, Maria Santagati, Stefania Stefani, Francesco Torino, Giuseppe Luigi Banna, Giuseppe Tonini, Massimo Libra

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancers, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 286 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
286citing papers in PubMed, 2 pooled it
27.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

286 citing papers in PubMed, 2 syntheses or guidelines pooled it, 563 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Review
  6. Article
  7. Breast Cancer and Metabolic Dysfunction-Associated Steatotic Liver Disease.International journal of molecular sciences · 2026
    Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Probiotics Cancer Interaction, Prevention, and Therapy.Immunity, inflammation and disease · 2026
    Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Frontiers in molecular biosciences · 2026
    Article
  18. Review
  19. Review
  20. Review

226 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Silvia VivarelliDepartment of Biomedical and Biotechnological Sciences, Oncologic, Clinic and General Pathology Section, University of Catania, 95123 Catania, Italy. silvia.vivarelli7@gmail.com.ORCID 0000-0001-9363-6523
Rossella SalemiDepartment of Biomedical and Biotechnological Sciences, Oncologic, Clinic and General Pathology Section, University of Catania, 95123 Catania, Italy. rossellasalemi@alice.it.
Saverio CandidoDepartment of Biomedical and Biotechnological Sciences, Oncologic, Clinic and General Pathology Section, University of Catania, 95123 Catania, Italy. scandido@unict.it.
Luca FalzoneDepartment of Biomedical and Biotechnological Sciences, Oncologic, Clinic and General Pathology Section, University of Catania, 95123 Catania, Italy. luca.falzone@unict.it.
Maria SantagatiDepartment of Biomedical and Biotechnological Sciences, Section of Microbiology, University of Catania, 95123 Catania, Italy. m.santagati@unict.it.ORCID 0000-0003-1491-4973
Stefania StefaniDepartment of Biomedical and Biotechnological Sciences, Section of Microbiology, University of Catania, 95123 Catania, Italy. stefanis@unict.it.ORCID 0000-0003-1594-7427
Francesco TorinoDepartment of Systems Medicine, Medical Oncology, Tor Vergata University of Rome, 00133 Rome, Italy. torino@med.uniroma2.it.
Giuseppe Luigi BannaDivision of Medical Oncology, Cannizzaro Hospital, 95126 Catania, Italy. gbanna@yahoo.com.
Giuseppe ToniniDepartment of Medical Oncology, University Campus Bio-Medico of Rome, 00128 Rome, Italy. G.Tonini@unicampus.it.
Massimo LibraDepartment of Biomedical and Biotechnological Sciences, Oncologic, Clinic and General Pathology Section, University of Catania, 95123 Catania, Italy. mlibra@unict.it.
University of Catania · ITOspedale Cannizzaro · ITUniversità Campus Bio-Medico · ITUniversity of Rome Tor Vergata · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer is a multifactorial pathology and it represents the second leading cause of death worldwide. In the recent years, numerous studies highlighted the dual role of the gut microbiota in preserving host's health. Gut resident bacteria are able to produce a number of metabolites and bioproducts necessary to protect host's and gut's homeostasis. Conversely, several microbiota subpopulations may expand during pathological dysbiosis and therefore produce high levels of toxins capable, in turn, to trigger both inflammation and tumorigenesis. Importantly, gut microbiota can interact with the host either modulating directly the gut epithelium or the immune system. Numerous gut populating bacteria, called probiotics, have been identified as protective against the genesis of tumors. Given their capability of preserving gut homeostasis, probiotics are currently tested to help to fight dysbiosis in cancer patients subjected to chemotherapy and radiotherapy. Most recently, three independent studies show that specific gut resident species may potentiate the positive outcome of anti-cancer immunotherapy. The highly significant studies, uncovering the tight association between gut microbiota and tumorigenesis, as well as gut microbiota and anti-cancer therapy, are here described. The role of the

Indexed as

anti-cancer therapycancerinflammasomesintegrated therapyLactobacillus rhamnosus GGmicrobiomemicrobiotaprobiotics

Identifiers

PMID30609850
PMCPMC6356461
OpenAlexW2906724057

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.